DOCSLIB.ORG

Prucalopride (Resolor) for Chronic Constipation December 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prucalopride (Resolor) for Chronic Constipation December 2008 Prucalopride (Resolor) for chronic constipation December 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The National Horizon Scanning Centre Research Programme is part of the National Institute for Health Research December 2008 National Horizon Scanning Centre News on emerging technologies in healthcare Prucalopride (Resolor) for chronic constipation Target group • Chronic constipation: in adults whom laxatives fail to provide adequate relief. Technology description Prucalopride (Resolor) is a selective, high-affinity, enterokinetic 5-HT4 receptor agonist, which increases colon motility and restores the slow movement of the bowels. Prucalopride is an oral formulation administered at 1 or 2mg once daily and is intended to be used in laxative-refractory patients. Innovation and/or advantages Prucalopride is a first-in-class drug for this indication with a novel mechanism of action. While, none of the clinical trials compare the efficacy of prucalopride with current therapies, the drug was studied in patients who were dissatisfied with current laxatives. Developer Movetis NV. Availability, launch or marketing dates, and licensing plans: The company submitted a Marketing Authorisation Application with the EMEA in May 2008. NHS or Government priority area: This topic is relevant to The National Services Framework for Older People (2001). Relevant guidance • Clinical Knowledge Summaries. Constipation-care guidelines. 20081. • World Gastroenterology Organisation. Constipation-care guidelines. 20072. Clinical need and burden of disease The prevalence of constipation is difficult to estimate and varies widely depending on the definition and criteria employed, and whether self-assessment or physician-diagnosis is used. Estimates of the UK prevalence of constipation vary between 8.2% and 52% in women3. Constipation is more common in women than men, increases with age (estimated prevalence of 20% in elderly), and is higher amongst those living in nursing homes4. Health-related quality of life in people with constipation is generally worse than those without constipation5. Constipation generates around 450,000 GP consultations per year in England and Wales at an estimated cost of £4.5 million6. In 2007, approximately 15 million prescriptions were filled for laxatives, at a cost of almost £64 million in England and Wales7,8. The company estimate that about 363,000 patients in the UK are eligible to benefit from prucalopride based on an average prevalence of 7.7% for severe chronic constipation and assuming that 10% of patients with constipation are refractory to laxatives, which may be an over estimate. Existing comparators and treatments The current treatment options for chronic constipation include: • Dietary and lifestyle changes. 2 December 2008 National Horizon Scanning Centre News on emerging technologies in healthcare • Bulk-forming laxatives, e.g. Ispaghula Husk. • Stimulant laxatives, e.g. Bisacodyl. • Faecal softeners, e.g. Liquid paraffin, Arachis Oil. • Osmotic laxatives, e.g. Lactulose. Efficacy and safety Trial PRU-INT-6; PRU-USA-13; PRU-USA-11; NCT004881379: NCT0048594010: NCT0048388611: prucalopride vs placebo; prucalopride vs placebo; prucalopride vs placebo; phase III. phase III. phase III. Sponsor Movetis. Movetis. Movetis. Status Completed, published12. Completed, published13. Completed, published5. Location USA, Canada, EU (inc UK), USA. USA. Australia, Norway and South Africa. Design Randomised, double-blind, Randomised, double-blind, Randomised, double-blind, placebo controlled. placebo controlled. placebo controlled. Participants n=720; adults; constipation n= 641; adults; constipation n= 628; adults; constipation in trial <2 SCBM per week for ≥6 <2 SCBM per week for ≥6 <2 SCBMa per week for ≥6 months. months. months. Randomised to prucalopride Randomised to prucalopride Randomised to prucalopride 2mg, 4mg or placebo once 2mg, 4mg or placebo once 2mg, 4mg or placebo once daily for 12 weeks. daily for 12 weeks. daily for 12 weeks. Follow-up 12 week treatment period. 12 week treatment period. 12 week treatment period. Primary ≥3 SCBM per week. ≥3 SCBM per week. ≥3 SCBM per week. outcome Secondary ≥1 SCBM per week; ≥1 SCBM per week; ≥1 SCBM per week; outcomes symptom severity; and symptom severity; and symptom severity; and QOL. QOL. QOL. Key results ≥3 SCBM per week in ≥3 SCBM per week in ≥3 SCBM per week in weeks 1-12: 19.5% (p≤0.01 weeks 1-12: 23.9% (p≤0.01 weeks 1-12: 28.9% vs placebo), 23.6% vs placebo), 23.5% (p≤0.01 (p≤0.001 vs placebo), (p≤0.001 vs placebo) and vs placebo) and 12.1% of 28.9% (p≤0.001 vs placebo) 9.6% of prucalopride 2mg, prucalopride 2mg, 4mg and and 13.0% for prucalopride 4mg and placebo placebo respectively. 2mg, 4mg and placebo respectively. Mean change Improvement ≥1 on PAC- respectively. in overall PAC-SYM score SYM score at week 12: PAC-SYMc score at week at week 12: -0.66 (p≤0.001 38.0% (p≤0.001 vs 4: 31.4% (p≤0.001 vs vs placebo), -0.71 (p≤0.001 placebo), 29.1% and 23.6% placebo), 34.9% (p≤0.001 vs placebo) and respectively. Improvement vs placebo) and 15.1% -0.37 respectively. ≥1 on overall PAC-QOLb respectively. Improvement ≥1 on overall score at week 12: 43.5% Improvement ≥1 on PAC- PAC-QOL score at week (p≤0.001 vs placebo), SYM score at week 12: 12: 33.5% (p≤0.001 vs 44.4% (p≤0.001 vs placebo) 31.2%, 33.5%, 23.1% placebo), 29.4% (p≤0.001 and 26.0% respectively. respectively (non- vs placebo) and 16.4% significant). Improvement respectively. ≥1 on overall PAC-QOLd score at week 12: 39.4% a SCBM: spontaneous complete bowel movements b PAC-QOL: patient assessment of constipation-quality of life c PAC-SYM: patient assessment of constipation – symptoms questionnaire d PAC-QOL: patient assessment of constipation –quality of life 3 December 2008 National Horizon Scanning Centre News on emerging technologies in healthcare (p≤0.001 vs placebo), 40.5% (p≤0.001 vs placebo) and 21.7% respectively. Adverse Most frequently reported Most frequently reported Most frequently reported effects (AEs) AEs included headache, AEs included headache, AEs included headache, nausea, diarrhoea and nausea, diarrhoea, flatulence nausea, diarrhoea, flatulence abdominal pain. AEs in and abdominal pain. Severe and abdominal pain. 71.4%, 74.8% and 67.1% AEs in 15%, 21% and 10% Discontinuation rate of for prucalopride 2mg, 4mg for prucalopride 2mg, 4mg 8.2% with prucalopride 2mg and placebo respectively. and placebo respectively. compared to 1.9% in Discontinuation rate of Discontinuation rate of 4%, placebo. 6.3%, 15.1% and 6.7% 6% and 2% respectively. respectively. Trial PRU-USA-28; PRU-INT-12; PRU-USA-25; NCT0059833814: NCT0048742215: NCT0057701816: prucalopride vs. placebo; re- prucalopride vs. placebo; prucalopride vs. placebo; treatment; phase III. phase III. phase III. Sponsor Movetis. Movetis. Movetis. Status Completed, conference Completed, conference Completed, not published. abstract17. abstract18. Location USA. EU (inc UK), Canada, USA. Norway and South Africa. Design Randomised, double-blind, Randomised, double-blind, Randomised, double-blind, placebo controlled. placebo controlled. placebo controlled. Participants n= 516; adults; constipation n= 303; adults >65 years; n=755; adults; constipation in trial <2 SCBM per week for ≥6 constipation <2 SCBM per <2 SCBM per week for ≥6 months. week for ≥6 months. months. Randomised to prucalopride Randomised to prucalopride Randomised to 4mg or placebo once daily 1mg, 2mg, 4mg or placebo prucalopride 1mg for 2 for 4 weeks (Trt I), 2 week once daily for 4 weeks. days, 2mg for 2 days and 4 wash out period and second mg once daily thereafter, or 4 week (weeks 7-10) prucalopride 4mg once treatment period (Trt II). daily or placebo. Follow-up 8 week treatment period. 4 week treatment period. 4 week treatment period. Primary ≥3 SCBM per week. ≥3 SCBM per week. ≥3 SCBM per week. outcome Secondary ≥1 SCBM per week; ≥1 SCBM per week; ≥1 SCBM per week; outcomes symptom severity; and symptom severity; and symptom severity; and QOL. QOL. QOL. Key Results ≥3 SCBM per week: weeks ≥3 SCBM per week in - 1-4 (Trt I); 38.6% (p≤0.001 weeks 1-4: 39.5%, 32.0%, vs placebo) and 10.7% for 31.6% and 20.0% for prucalopride and placebo prucalopride 1mg, 2mg,4mg respectively. Weeks 7-10 and placebo respectively (Trt II): 36.0% (p≤0.001 vs. (non-significant). placebo) and 11.2% for 1≥ SCBM per week in prucalopride and placebo. weeks 1-4 : 61.1% (p≤0.05 vs placebo), 56.9% (p≤0.05 vs placebo), 50.7% (p≤0.05 vs placebo) and 33.8 % respectively. Expected - - Study started August 1998 reporting and completed September date 1999. 4 December 2008 National Horizon Scanning Centre News on emerging technologies in healthcare Adverse Most frequently reported Most frequently reported - Effects AEs were gastrointestinal in AEs included headache and (AEs) nature and headache. nausea. There are 3 large, complete, but not fully published open-label long-term follow up trials of patients involved in phase II and III trials, and new recruits with 1, 2 or 4mg prucalopride for up to 24 months. There is a reported maintenance of patient satisfaction and quality of life improvement. Predominant adverse effects remain mostly gastro- intestinal and are more frequent in new recruits to the trial. Estimated cost and cost impact The cost of prucalopride is yet to be determined. The costs of other products used in constipation are: Drug Dose Estimated cost per 12 weeks19 Fybogel 1 sachet daily £6.36 Bisacodyl 5-10mg daily £2.70-£5.40 Lactulose 15ml twice daily £13.15 Potential or intended impact – speculative Patients ; Reduced morbidity Reduced mortality or increased ; Improved quality of life for survival patients and/or carers Quicker, earlier or more accurate Other: None identified diagnosis or identification of disease Services Increased use Service reorganisation required Staff or training required ; Decreased use: reduction of Other: None identified number of visits to GPs and/or specialists.
Load more

Recommended publications
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • And Dietary Measures Literature Review on the Effect of Laxative Treatment
    Downloaded from adc.bmj.com on 28 August 2008 Currently recommended treatments of childhood constipation are not evidence based. A systematic literature review on the effect of laxative treatment and dietary measures Maaike A. M. Pijpers, Merit Tabbers, Marc A. Benninga and Marjolein Y. Berger Arch. Dis. Child. published online 19 Aug 2008; doi:10.1136/adc.2007.127233 Updated information and services can be found at: http://adc.bmj.com/cgi/content/abstract/adc.2007.127233v1 These include: Rapid responses You can respond to this article at: http://adc.bmj.com/cgi/eletter-submit/adc.2007.127233v1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Notes Online First contains unedited articles in manuscript form that have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Online First articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Online First articles must include the digital object identifier (DOIs) and date of initial publication. To order reprints of this article go to: http://journals.bmj.com/cgi/reprintform To subscribe to Archives of Disease in Childhood go to: http://journals.bmj.com/subscriptions/ Downloaded from adc.bmj.com on 28 August 2008 ADC Online First, published on August 19, 2008 as 10.1136/adc.2007.127233 Currently recommended treatments of childhood constipation are not evidence based. A systematic literature review on the effect of laxative treatment and dietary measures.
    [Show full text]
  • Assessment Report on Cassia Senna L
    European Medicines Agency Evaluation of Medicines for Human Use London, 27 April 2007 Doc. Ref. EMEA/HMPC/51868/2006 Corr. COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON CASSIA SENNA L. AND CASSIA ANGUSTIFOLIA VAHL, FOLIUM Herbal substance Cassia senna L. (C. acutifolia Delile) [Alexandrian or Khartoum senna] or Cassia angustifolia Vahl [Tinnevelly senna], folium (senna leaf) or a mixture of the two species Herbal preparation dried leaflets, standardised; standardised herbal preparations thereof Pharmaceutical forms Herbal substance for oral preparation Rapporteur Dr C. Werner Assessor Dr B. Merz Superseded 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. Introduction 3 II. Clinical Pharmacology 3 II.1 Pharmacokinetics 3 II.1.1 Phytochemical characterisation 3 II.1.2 Absorption, metabolism and excretion 4 II.1.3 Progress of action 5 II.2 Pharmacodynamics 5 II.2.1 Mode of action 5 • Laxative effect 5 II.2.2 Interactions 7 III. Clinical Efficacy 7 III.1 Dosage 7 III.2 Clinical studies 8 III.2.1 Constipation 8 III.2.2 Irritable bowel syndrome 10 III.2.3 Bowel cleansing 11 III.3 Clinical studies in special populations 15 III.3.1 Use in children 15 III.3.2 Use during pregnancy and lactation 16 III.4 Traditional use 17 IV.
    [Show full text]
  • Laxatives Or Methylnaltrexone for the Management of Constipation in Palliative Care Patients (Review)
    Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Candy B, Jones L, Goodman ML, Drake R, Tookman A This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 1 http://www.thecochranelibrary.com Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 4 OBJECTIVES ..................................... 4 METHODS...................................... 5 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 15 REFERENCES..................................... 15 CHARACTERISTICSOFSTUDIES . .. 17 DATAANDANALYSES. 28 Analysis 1.1. Comparison 1 Methylnaltrexone versus placebo, Outcome 1 Proportion who had rescue-free laxation within 4hours..................................... 28 Analysis 1.2. Comparison 1 Methylnaltrexone versus placebo, Outcome 2 Laxation within 24 hours. 29 Analysis 1.3. Comparison 1 Methylnaltrexone versus placebo, Outcome 3 Tolerability: proportion
    [Show full text]
  • Docusate Sodium
    HEAD 03150148P00290148L03-M045UWASS FRONT 1ST BAR 1ST BAR >> READ DIRECTION >> READ DIRECTION 100 mg Capsules docusate sodium LAST BAR LAST BAR Package Leaflet: Information for the user Read all of this leaflet carefully before you • Constipation is an occasional problem for start taking this medicine because it some people - for others, it may happen contains important information for you. more often Always take this medicine exactly as described • Constipation happens when the normal in this leaflet or as your doctor or pharmacist muscle actions in the bowel slow down has told you. The cause of constipation is often not known. • Keep this leaflet. You may need to read it It can be linked with: again • Pregnancy • Ask your pharmacist if you need more • Lack of exercise information or advice • Sudden change of diet • If you get any side effects, talk to your • A diet with not enough fibre doctor or pharmacist. This includes any • Having to stay in bed for a long time possible side effects not listed in this leaflet. • Medicines such as morphine or codeine See section 4 • Loss of ‘tone’ of the bowel muscles in older • You must talk to a doctor or pharmacist if people you do not feel better or you feel worse • The full name of your medicine is DulcoEase Whatever the cause, constipation can be 100 mg Capsules. In this leaflet the shorter uncomfortable. It may make you feel bloated name DulcoEase is used and heavy or generally ‘off colour’. Sometimes it causes headaches. What is in this leaflet: Try these healthy tips to help prevent 1.
    [Show full text]
  • Gastroenterologíayhepatología
    Document downloaded from http://www.elsevier.es, day 14/02/2018. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Gastroenterol Hepatol. 2017;40(4):303---316 Gastroenterología y Hepatología www.elsevier.es/gastroenterologia REVIEW Clinical practice guidelines for the management of constipation in adults. Part 2: Diagnosis ଝ,ଝଝ and treatment a,∗ b,c d e Jordi Serra , Juanjo Mascort-Roca , Mercè Marzo-Castillejo , Silvia Delgado Aros , f g h Juan Ferrándiz Santos , Enrique Rey Diaz Rubio , Fermín Mearin Manrique a Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain b CAP Florida Sud, Institut Català de la Salut, Hospitalet de Llobregat, Barcelona, Spain c Departament de Ciències Clíniques, Campus Bellvitge, Facultat de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain d Unitat de Suport a la Recerca --- IDIAP Jordi Gol. Direcció d’Atenció Primària Costa de Ponent, Institut Català de la Salut, Comité Científico de semFYC, Barcelona, Spain e Neuro-Enteric Translational Science (NETS) group coordinator. IMIM --- Parc de Salut Mar. PRBB, Barcelona, Spain f Subdirección General de Calidad Asistencial, Consejería de Sanidad, Madrid, Spain g Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain h Instituto de Trastornos Funcionales y Motores Digestivos, Servicio de Aparato Digestivo, Centro Médico Teknon, Barcelona, Spain Received 18 January 2016; accepted 5 February 2016 Available online 31 March 2017 KEYWORDS Abstract Constipation is a very common disorder that adversely affects well-being and quality Constipation; of life. Evidence-based clinical practice guidelines are an essential element for proper patient management and safe, effective treatment.
    [Show full text]
  • Original Article Sep 2010; Vol 20 (No 3), Pp: 291-296
    Iran J Pediatr Original Article Sep 2010; Vol 20 (No 3), Pp: 291-296 Comparing Oral Route Paraffin Oil versus Rectal Route for Disimpaction in Children with Chronic Constipation; a Randomized Control Trial Fatemeh Farahmand1,2, MD; Kambiz Eftekhari2, MD; Vajiheh Modarresi*2, MD; Mehri Najafi-Sani1,2, MD; Ahmad Khodadad1,2, MD, and Farzaneh Motamed1,2, MD 1. Department of Pediatrics, Faculty of medicine, Tehran University of Medical Sciences, Tehran, IR Iran 2. Pediatrics Center of Excellence, Children's Medical Center, Tehran, IR Iran Received: Sep 17, 2009; Final Revision: Nov 18, 2009; Accepted: Feb 10, 2010 Abstract Objective: Functional constipation is a common and challenging problem in pediatrics. Fecal disimpaction prior to maintenance therapy is recommended to ensure successful treatment. The aim of this study was to compare the efficacy and patient’s compliance of the two methods of paraffin oil administration (oral and rectal route) with the purpose of disimpaction in treatment of children with functional constipation. Methods: A total of 80 children (49 males and 31 females) aged 1-12 years, with functional constipation according to Rome III criteria, whose rectal examination confirmed fecal impaction were divided into two groups randomly. Group I received 3 ml/kg/day paraffin oil orally and group II received 3ml/kg/day paraffin oil rectally during 3 consequent days. Successful treatment was defined as no detectable fecal impaction in rectal examination after at most 72 hours. Patient compliance and family satisfaction also was evaluated using a scored questionnaire. Findings: Response to the treatment in both groups was with 92.5% and 82.5% in group I and II, respectively.
    [Show full text]
  • Senna (Cas No
    NTP REPORT ON THE TOXICOLOGY STUDY OF SENNA (CAS NO. 8013-11-4) IN C57BL/6NTAC MICE AND TOXICOLOGY AND CARCINOGENESIS STUDY OF SENNA IN GENETICALLY MODIFIED C3B6.129F1/Tac-Trp53tm1Brd N12 HAPLOINSUFFICIENT MICE (FEED STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 April 2012 NTP GMM 15 NIH Publication No. 12-5968 National Institutes of Health Public Health Service U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOREWORD The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Genetically Modified Model (GMM) Report series began in 2005 with studies conducted by the NTP. The studies described in the GMM Report series are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected agents in laboratory animals that have been genetically modified. These genetic modifications may involve inactivation of selected tumor suppressor functions or activation of oncogenes that are commonly observed in human cancers.
    [Show full text]
  • The Treatment of Constipation in Mental Hospitals
    Gut: first published as 10.1136/gut.3.1.85 on 1 March 1962. Downloaded from Gut, 1962, 3, 85 The treatment of constipation in mental hospitals L. R. C. HAWARD AND H. E. HUGHES-ROBERTS From Graylingwell Hospital, Chichester SYNOPSIS This study investigates the incidence of constipation in two representative mental institutions, and the effect, in one of the hospitals, restricting the use of laxatives to only one drug, namely, standardized senna (Senokot). The remarkable potentiality of Senokot for long-term re-educative programmes is reflected in the reduction from 44% of 210 patients receiving various laxatives regularly at the'start of the trial to 8 % after three months' treatment. The special studies showed that chronic psychotics could be freed from enemas and a substantial number (17 out of 24) cured of constipation; 31 patients on insulin therapy required maintenance doses during treatment but all were subsequently cured; of 25 patients with various neurological lesions, 21 were freed of laxative treatment with four only remaining on sub-laxative doses. There exists a two-way psychosomatic relationship large number of psychiatrists each possessing his whereby brain and bowel function influence each own idea of what constitutes the disorder, it was other. Alvarez (1948), for example, has shown that found necessary to employ the basis of the actual nervous tension particularly affects the bowel prescription of an aperient. http://gut.bmj.com/ muscles; conversely, Nobbs (1960) has found that a loaded bowel can cause mental confusion in the elderly and that the correction of constipation INCIDENCE restores the mental equilibrium. In examining the Forms were circulated to the pharmacy departments problems of bowel regularity in a mental hospital we of mental hospitals in England asking for details of are, therefore, studying a pertinent and not un- the use of laxatives.
    [Show full text]
  • Use of Polyethylene Glycol in Functional Constipation and Fecal Impaction Miguel Mínguez1, Antonio López Higueras2 and Javier Júdez3 1Department of Digestive Medicine
    1130-0108/2016/108/12/790-806 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS REV ESP ENFERM DIG © Copyright 2016. SEPD y © ARÁN EDICIONES, S.L. 2016, Vol. 108, N.º 12, pp. 790-806 REVIEW Use of polyethylene glycol in functional constipation and fecal impaction Miguel Mínguez1, Antonio López Higueras2 and Javier Júdez3 1Department of Digestive Medicine. Hospital Clínico. Universidad de Valencia. Valencia, Spain. 2Hospital General Universitario Morales Meseguer. Murcia, Spain. 3Knowledge Management. Sociedad Española de Patología Digestiva (SEPD). Madrid, Spain ABSTRACT INTRODUCTION Objective: The objective of this study was to evaluate in an Functional constipation (FC), defined by the Rome Cri- analytical and descriptive manner the evidence published so far on teria (1) as a chronic functional digestive condition, is a the use of polyethylene glycol (PEG), with or without electrolytes, in the management of functional constipation and the treatment serious problem for adults and children due both to its of fecal impaction. prevalence and to the concomitant reduction in quality of Methodology: Search on MEDLINE, EMBASE and Cochrane life. In addition, it implies a high pharmaceutical cost. databases until May 2016 of all publications adjusted to the follow- Likewise, fecal impaction can lead to a situation that ing terms: constipation AND/OR fecal impaction AND (PEG OR seriously compromises patient health, especially at extreme polyethylene glycol OR macrogol OR movicol OR idralax OR miralax OR transipeg OR forlax OR golytely OR isocolan OR ages, causing sometimes a vital risk. mulytely) NOT colonoscopy. Critical reading of selected articles In order to treat these pathologies, a variety of resources (English or Spanish), sorting their description according to group has been employed, including pharmaceutical resources age (adult/pediatric age) and within those, in accordance with study and others that directly impinge upon patient life habits.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Prucalopride (Resolor) for Adult Males with Chronic Constipation – Third Line
    Horizon Scanning Centre September 2014 Prucalopride (Resolor) for adult males with chronic constipation – third line SUMMARY NIHR HSC ID: 10238 Prucalopride (Resolor) is intended to be used as third line therapy for the treatment of chronic constipation in adult males. If licensed, it would offer an additional treatment option for this patient group who do not respond to at least two previous laxative treatments. Prucalopride is a highly selective This briefing is serotonin 5-HT4 receptor antagonist that has demonstrated prokinetic properties on gastric, intestinal and colonic smooth muscle. Prucalopride is based on currently licensed for the treatment of chronic constipation in women in information whom laxatives fail to provide adequate relief. available at the time of research and a It is estimated that the prevalence of chronic constipation is 16%. It is more limited literature common in women than men and prevalence increases with age. Patients search. It is not with constipation report a decreased quality of life, more job absenteeism, intended to be a and loss of work productivity. In 2012, there were 60,567 admissions for definitive statement constipation in England, resulting in 151,319 bed days and 72,567 finished on the safety, consultant episodes; in the same year there were 58 deaths registered in efficacy or England and Wales due to constipation. effectiveness of the health technology Management of chronic constipation may involve dietary and lifestyle covered and should changes in addition to medication such as bulk-forming laxatives, stimulant not be used for laxatives, osmotic laxatives or faecal softeners. When oral laxative therapy is commercial ineffective, use of suppositories, enemas, lubiprostone, prucalopride (for purposes or women), rectal irrigation or manual disimpaction may be appropriate.
    [Show full text]